The outcomes of these events dramatically impact the competitive landscape of late-stage drug development and impact the stock prices of many market players, especially smaller companies. Therefore, the sooner you know about them, the better.
Discover the 10-20 most important expected pharma and biotech events in the coming 3 months and you will be able to predict the future pharma landscape.
Biomedtracker is the leader in providing objective information alongside evidence-based clinical assessments and investment research on pipeline drugs worldwide.
Discover the catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. Learn each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group.
Indications covered are:
• Alzheimer's Disease (AD)
• Bladder Cancer
• Community Acquired Pneumonia (CAP) (Antibacterial)
• Congestive Heart Failure (CHF) and Cardiomyopathies
• Crohn's Disease
• Diabetes Mellitus, Type I
• Diabetes Mellitus, Type II
• Dyslipidemia / Hypercholesterolemia
• Friedreich's Ataxia
• Hepatitis B (HBV) Treatment (Antiviral)
• Hepatitis B Prevention (Vaccines, Antiviral)
• Immune Thrombocytopenic Purpura (ITP)
• Irritable Bowel Syndrome (IBS)
• Ischemic Stroke
• Moderate to Severe Pain
• Multiple Sclerosis (MS)
• Neuroendocrine Tumors (NET)
• Non-Small Cell Lung Cancer (NSCLC)
• Peripheral Arterial Disease (PAD)
• Rheumatoid Arthritis (RA)
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: